Company intelligence / Profile preview
TRACON Pharmaceuticals, Inc.
San Diego, California, USAtraconpharma.com ↗
- Ownership
- Public · TCON
- Employees
- ~20
- Development stage
- Other
01
Overview
TRACON’s lead program envafolimab failed to meet its primary endpoint in the pivotal Phase II ENVASARC trial for refractory soft tissue sarcomas in July 2024 and all related development was discontinued. The company’s small molecule DNA repair inhibitor TRC102 showed activity in recurrent glioblastoma but remained investigational through NCI-sponsored trials. The company entered formal liquidation and dissolution by shareholder vote in November 2024.
- Therapeutic areas
- GastroenterologyOncologyOphthalmologyHematology
- Modalities
- Monoclonal antibodies (mAbs)Small moleculesBispecific antibodies (preclinical)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Janssen Pharmaceutica N.V. / J&J (for TRC253)National Cancer Institute/NCI CRADA partnership for multiple trials with TRC102Alphamab Oncology & Jiangsu Alphamab Biopharmaceuticals /3D Medicines Co., Ltd. (licensing envafolimab)Eucure Biopharma/Biocytogen/Eucure partnership on YH001I-Mab Biopharma collaboration on TJ004309/bispecifics
Beyond the preview
Go deeper on TRACON Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRACON Pharmaceuticals, Inc..